PULSUS Group collaborates with Anbu Kochi to Contribute towards Kerala Flood Victims

Food and Healthcare Press Releases Thursday September 20, 2018 11:53
SINGAPORE and LONDON--20 Sep--PRNewswire/InfoQuest
  • Anbu Kochi joins hands with PULSUS Group in support of Kerala Flood Victims

In a humanitarian effort, PULSUS Group - in collaboration with Anbu Kochi - is responding to the calamity of the recent, unprecedented floods in the Indian state of Kerala by providing contributions to aid relief and rehabilitation measures. PULSUS Group took initiative to extend a helping hand in donating clothes, food items, medicines, sanitation, hygiene products including edibles (baby food, ORS packets/electrolytes, rusk, biscuits), and non-edibles (anti-septic lotion, bleaching powder/lime powder, baby diapers, adult diapers, sanitary napkins, toothpaste, tooth brushes, body soap, washing soap, clothes old/new, water cans, candles and match boxes). PULSUS Group and Anbu Kochi are collecting daily essentials and other relief materials to help Kerala flood victims. PULSUS Group and Anbu Kochi stand for Kerala in helping the flood victims with necessities and donations.

In addition, all the employees at PULSUS Group have generously raised funds for the cause. Dr. Srinubabu Gedela, CEO, Pulsus & Omics International, addressing the issue has said, "What Kerala has experienced today is unparalleled by any of the disasters that the state had suffered in recent times. We take social responsibility to stand by them. Rebuilding the state can take years to come. Every rupee and contribution donated goes towards the wellbeing and uplifting of the state. Our thoughts and prayers are with flood relief victims, displaced, homeless families and the needs of the hour require our call of action to address their immediate needs to provide shelter, livelihood, and non-food items."

About PULSUS Group: PULSUS Group is an internationally renowned peer-review publisher and conferences organizer operational since 1984. Headquartered at Singapore, PULSUS Group has its offices in London (UK), Ontario (Canada) and Chennai, Gurgaon, Hyderabad (India). Endorsed by the medical associations and scientific societies, PULSUS promotes peer reviewed medical journals in association with international medical associations and scientific societies. PULSUS organizes 500+ global meetings per year across the world, enables physicians and industry professionals to convene together and form conclusive strategies towards advanced therapeutics and treatment aspects. PULSUS Group strives to reach out to broad range of target groups and market leaders across diverse spectrum of research fields, providing high quality information across USA, Europe, Asia Pacific and ME.

For media queries, write to: contactus@pulsus.com Ph: 650-268-9744
Logo - https://mma.prnewswire.com/media/544592/PULSUS_Logo.jpg

Latest Press Release

Open nursing course to accelerate the safe practice of Peripheral Intravenous Cannula Insertion

"Peripheral Intravenous Cannula Insertion is a very broad term and not likely to be understood by people outside the medical community. In simple terms, it means the provision of saline, medication or blood products through an intravenous device and...

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres(R) Y-90 resin microspheres

- Physicians and employees recognized for their role in this milestone and impact made on patient lives Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres(R)...

Most Thai consumers want to improve their diets and are open to healthier product reformulation

According to a new report by Food Industry Asia (FIA) and research firm IGD, almost all consumers in Thailand (99 per cent) are interested in improving their diets and a majority (82 per cent) are happy for products to be reformulated, provided that...

Kemin Launches New Vision and Logo for the Future

Global ingredient manufacturer sets sights on sustainably transforming 80 percent of the world by 2042 Today Kemin Industries, a global ingredient manufacturer, unveiled its new global vision and logo to align the company strategically for 2042 and...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The...

Related Topics